Anna D. Garrett, PharmD, BCPS

A small study of patients undergoing bariatric surgery suggests that weekly warfarin doses can change by as much as 20% postoperatively.

Ticagrelor is shown to be better at platelet inhibition. Warfarin seen as beneficial to patients with PAH. Dabigatran's problems aren't over.

Fondaparinux shown to be safe for patients with renal impairment.

FDA says no to rivaroxaban for ACS. ACCP updates DVT evidence. Fatal bleeds from dabigatran have tapered off

The debate on CHADS2 scoring vs. CHA2DS2-VASc continues